Answers are grounded in this paper and cite their sources.
Molecular profiling is central to pediatric precision oncology, yet only 15-20% of patients benefit from biology-guided treatments. This limitation underscores the urgent need for functional precision medicine, which interrogates therapeutic vulnerabilities using patient-derived models. Despite hurdles in establishing these models, such as limited biopsy material and technical screening barriers, recent advances in tumoroids, patient-derived xenografts and high-throughput platforms offer an unprecedented opportunity to bridge the translational gap. In this review, we describe the evolution of patient-derived models of pediatric brain cancers, their current strengths and weaknesses and the technological innovations redefining the field. Together, these insights provide a road map for integrating functional data into clinical decision-making, ultimately aiming to 'cure more and heal better' children with brain tumors.
No takes yet. Share an insight, caveat, or question.
Lafont et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: